IP Library Granted Patent US 8,829,038
Granted Patent B2
US 8,829,038 · App. 13/852,513 · Granted Sep 9, 2014

Parasiticidal formulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,829,038
App. No.
13/852,513
Granted
Sep 9, 2014
Kind
B2
Abstract

The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C 1 -C 6 alcohol co-solvent, wherein the total amount of C 1 -C 6 alcohol is up to 8% by weight of the formulation; at least one organic solvent which is not the C 1 -C 6 alcohol co-solvent; and at least one crystallization inhibitor, wherein the total amount of crystallization inhibitor is from 2 to 20% by weight of the formulation. The formulations of the invention have higher flash points than known parasiticidal formulations comprising Fipronil and therefore provide safer formulations for use in the home, storage, manufacture and distribution.

Claims (23)

1. A parasiticidal formulation comprising:

from about 8 to about 12% by weight Fipronil, or a veterinary acceptable derivative thereof; less than about 5% by weight of the formulation of ethanol; and

at least one organic solvent which is not ethanol.

2. The formulation of claim 1 , further comprising one or more crystallization inhibitor.

3. The formulation of claim 1 , wherein the Fipronil or a veterinarily acceptable derivative thereof is Fipronil.

4. The formulation of claim 1 , which further comprises an insect growth regulator (IGR).

5. The formulation of claim 4 , wherein the IGR is s-methoprene.

6. The formulation of claim 5 wherein the amount of S-methoprene is from about 5% to about 25% by weight of the formulation.

7. The formulation of claim 1 wherein the at least one organic solvent which is not ethanol is diethylene glycol monoethyl ether, ethylene glycol monoethyl ether, dipropylene glycol n-butyl ether, dipropylene glycol monomethyl ether, or combinations thereof.

8. The formulation of claim 7 wherein the at least one organic solvent which is not ethanol is diethylene glycol monoethyl ether.

9. The formulation of claim 1 further comprising at least one antioxidant.

10. The formulation of claim 9 comprising at least two antioxidants.

11. The formulation of claim 9 wherein the at least one antioxidant is selected from the group consisting of butylated hydroxylanisole, butylated hydroxyltoluene, alpha tocopheral, ascorbic acid, ascobyl palmitate, fumeric acid, malic acid, citric acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, and monothioglycerol.

12. The formulation of claim 10 wherein the at least two antioxidants are independently selected from the group consisting of butylated hydroxylanisole, butylated hydroxyltoluene, alpha tocopheral, ascorbic acid, ascobyl palmitate, fumeric acid, malic acid, citric acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, and monothioglycerol.

13. The formulation of claim 11 wherein the at least one antioxidant is butylated hydroxylanisole or butylated hydroxyltoluene.

14. The formulation of claim 13 wherein the at least one antioxidant is butylated hydroxylanisole.

15. The formulation of claim 13 wherein the at least one antioxidant is butylated hydroxyltoluene.

16. The formulation of claim 12 wherein the at least two antioxidants are butylated hydroxyltoluene and butylated hydroxylanisole.

17. The formulation of claim 1 , wherein the formulation is formulated for spot-on delivery.

18. The formulation of claim 2 , wherein the one or more crystallization inhibitors is selected from the group consisting of polyethylene glycols, polyethylene glycol hydrogenated castor oil, polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate, invylpyrrolidone, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated soribtan esters, ployoxyethylenated hydrogenated castor oil, lecithin, sodium carboxymethylcellulose, methacrylates and combinations thereof.

19. The formulation of claim 18 wherein the at least one crystallization inhibitor is polyethylene glycols, polyethylene glycol hydrogenated castor oil, or combinations thereof.

20. The formulation of claim 19 wherein the at least one crystallization inhibitor is polyethylene glycols and polyethylene glycol hydrogenated castor oil.

21. The formulation of claim 20 wherein the amount of polyethylene glycol is about 5% by weight of the formulation and the amount of polyethylene glycol hydrogenated castor oil is about 5% by weight of the formulation.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2024
From: JEFFERIES FINANCE LLC
To: PETIQ HOLDINGS, LLC; PETIQ, LLC; SERGEANT’S PET CARE PRODUCTS, LLC; COMMUNITY VETERINARY CLINICS, LLC; FIDOPHARM, INC.; TRURX LLC; VELCERA, LLC
Reel/Frame 069052/0290 →
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2024
From: KEYBANK NATIONAL ASSOCIATION
To: PETIQ HOLDINGS, LLC; PETIQ, LLC; SERGEANT’S PET CARE PRODUCTS, LLC; COMMUNITY VETERINARY CLINICS, LLC; FIDOPHARM, INC.; TRURX LLC; VELCERA, LLC
Reel/Frame 069269/0614 →
FIRST LIEN PATENT SECURITY AGREEMENT (TL) Recorded Oct 28, 2024
From: PETIQ, INC.; PETIQ, LLC; TRURX LLC; VELCERA, LLC; FIDOPHARM, INC.; SERGEANT’S PET CARE PRODUCTS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069272/0659 →
ABL PATENT SECURITY AGREEMENT Recorded Oct 28, 2024
From: PETIQ, INC.; PETIQ, LLC; TRURX LLC; VELCERA, LLC; FIDOPHARM, INC.; SERGEANT’S PET CARE PRODUCTS, LLC
To: KEYBANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 069272/0670 →
SECURITY INTEREST Recorded Apr 14, 2021
From: PETIQ HOLDINGS, LLC; PETIQ, LLC; SERGEANT'S PET CARE PRODUCTS, LLC; COMMUNITY VETERINARY CLINICS, LLC; FIDOPHARM, INC.; TRURX LLC; VELCERA, LLC
To: JEFFERIES FINANCE LLC
Reel/Frame 055915/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2013
From: DONNELLY, MARTIN BENEDICT GEORGE
To: OMNIPHARM LIMITED
Reel/Frame 030874/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2013
From: CIPLA LIMITED
To: OMNIPHARM LIMITED
Reel/Frame 030874/0665 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2013
From: QEDETAL LIMITED
To: FIDOPHARM, INC.
Reel/Frame 030874/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2013
From: OMNIPHARM LIMITED
To: FIDOPHARM, INC.
Reel/Frame 030874/0683 →